Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Thalidomide off-label coverage

Executive Summary

"I think we are making a lot of progress" in working with CMS to gain coverage for thalidomide for cancer in replacement drug demonstration project under Medicare Part B, Sen. Kay Bailey Hutchison (R-Tex.) tells the Blood Cancer Coalition May 19. Under CMS proposed demonstration, Medicare would cover only FDA-approved indications for oral cancer drugs (1"The Pink Sheet" April 19, 2004, p. 29). Thalidomide (Celgene's Thalomid) is approved only for the cutaneous symptoms of leprosy but is widely used for multiple myeloma...

You may also be interested in...

Medicare Part B Oral Chemotherapy Demo Limited To Approved Indications

Reimbursement for oral chemotherapy products under a Medicare Part B demonstration project will be limited to FDA-approved indications, the Centers for Medicare & Medicaid Services' proposed criteria say

Teva Debuts US Azopt Rival

Teva has launched the first and so far only US generic version of Novartis’ Azopt treatment for ocular hypertension, with the brinzolamide 1% solution having been developed and manufactured by Indoco Remedies.

EU MDR Notified Body Designations Could Soar By A Third By End Of 2021

There could be 28 notified body designations in total under the Medical Device Regulation by the end of 2021. But there is cause for concern over designations under the IVD Regulation, which are lagging far behind.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts